(Q40909295)

24 September 2017

title

Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines (English)

1 reference

ORCID Public Data File 2021

24 September 2017

1 reference

1 reference

1 reference

author name string

Meco D

1

1 reference

24 September 2017

Lasorella A

2

1 reference

24 September 2017

Riccardi A

3

1 reference

24 September 2017

Servidei T

4

1 reference

24 September 2017

Mastrangelo R

5

1 reference

24 September 2017

Riccardi R

6

1 reference

24 September 2017

publication date

1 August 1999

1 reference

European Journal of Cancer

24 September 2017

published in

1 reference

24 September 2017

volume

35

1 reference

24 September 2017

issue

8

1 reference

24 September 2017

page(s)

1227-1234

1 reference

Trends in survival for childhood cancer in Britain diagnosed 1971-85

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Treatment of neuroblastoma with 131I-metaiodobenzylguanidine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

The treatment of neuroblastoma with 131I-MIBG

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Carboplatin as a potentiator of radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Maturation of neuroblastoma to ganglioneuroma in lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Induction of neuroblastoma maturation by a new chemotherapy protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Induction of teratocarcinoma F9 cell differentiation with cis-diammine dichloroplatinum(II) (CDDP)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Morphometric analysis of cisplatin-induced neurite outgrowth in N1E-115 neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900078-7

7 January 2021

10.1016/S0959-8049(99)00078-7

Identifiers

DOI

1 reference

24 September 2017

1 reference